Diagnostic Utility of IMP3 Expression in Thyroid Neoplasms
- 1 June 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Diagnostic Molecular Pathology
- Vol. 19 (2), 63-69
- https://doi.org/10.1097/pdm.0b013e3181b6a528
Abstract
The capability of molecular markers to differentiate between benign and malignant well-differentiated thyroid tumors remains unclear. The aim of this study was to evaluate the use of insulin-like growth factor II mRNA binding protein-3 (IMP3) mRNA expression to distinguish benign from malignant thyroid tumors. RNA samples from 80 formalin-fixed, paraffin-embedded thyroid tissues, including 22 usual papillary thyroid carcinomas (PTCs), 18 follicular variants of PTC, 5 follicular thyroid carcinomas, 33 follicular adenomas, and 2 hyperplastic nodules, were used for quantitative reverse transcription-polymerase chain reaction (qRT-PCR) analysis. IMP3 mRNA expression levels in thyroid tumors were expressed as relative fold change (fold) after normalization with normal thyroid RNA. The results showed that thyroid carcinomas including PTC, follicular variants of PTC, and follicular thyroid carcinomas have significantly higher IMP3 expression levels with 48.3, 35.3, and 43.8 fold, respectively, compared with benign thyroid lesions (2.8 fold). Using the IMP3 expression value of 5 fold as a cutoff point to separate benign and malignant thyroid tumors, IMP3 qRT-PCR analysis had a 91.4% clinical specificity and 86.7% clinical sensitivity for the diagnosis of well-differentiated thyroid carcinomas. Conventional RT-PCR and immunohistochemical analysis for IMP3 in a subset of cases supported the qRT-PCR results. These results indicate that detection of IMP3 mRNA expression levels by qRT-PCR may be a useful molecular marker to assist in the diagnosis of well-differentiated thyroid carcinomas.Keywords
This publication has 33 references indexed in Scilit:
- Combination of Quantitative IMP3 and Tumor Stage: A New System to Predict Metastasis for Patients with Localized Renal Cell CarcinomasClinical Cancer Research, 2008
- RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinomaHepatology, 2008
- Oncofetal protein IMP3Cancer, 2008
- External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinomaCancer, 2008
- Use of IMP3 in identification of carcinoma in fine needle aspiration biopsies of pancreas.Acta Cytologica, 2008
- Extrapulmonary small cell carcinomas express K homology domain containing protein overexpressed in cancer, but carcinoid tumors do notHuman Pathology, 2007
- Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective studyThe Lancet Oncology, 2006
- KOC (K Homology Domain Containing Protein Overexpressed in Cancer)The American Journal of Surgical Pathology, 2005
- Expression of the highly conserved RNA binding protein KOC in embryogenesisMechanisms of Development, 1999
- A Family of Insulin-Like Growth Factor II mRNA-Binding Proteins Represses Translation in Late DevelopmentMolecular and Cellular Biology, 1999